Johnson & Johnson Submits Emergency Use Authorization Amendment to FDA Supporting COVID-19 Booster Vaccine
The phase 3 ENSEMBLE 2 study found that a booster of Johnson & Johnson's single-shot vaccine administered 56 days after the primary dose provided 94% protection ...
from Google Alert - Business https://ift.tt/3lkuU7n
The phase 3 ENSEMBLE 2 study found that a booster of Johnson & Johnson's single-shot vaccine administered 56 days after the primary dose provided 94% protection ... https://ift.tt/eA8V8J
from Google Alert - Business https://ift.tt/3lkuU7n
The phase 3 ENSEMBLE 2 study found that a booster of Johnson & Johnson's single-shot vaccine administered 56 days after the primary dose provided 94% protection ... https://ift.tt/eA8V8J
Comments
Post a Comment